Cetuximab + Gemox in Biliary Tract Cancer

Status Completed

Clinical Trial Summary

The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.

Clinical Trial Description

Primary Objective(s) The primary objective of the study is to evaluate the best overall response of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients with advanced or metastatic biliary tract cancer.

Secondary Objectives

The secondary objectives of this study are as follows:

- toxicity

- secondary resection rate

- progression-free survival (PFS)

- overall survival (OS) ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01216345
Study type	Interventional
Source	Association of Research on the Biology of Liver Tumors
Contact
Status	Completed
Phase	Phase 2
Start date	October 2006
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05679674` - Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer	N/A
Recruiting	`NCT04585750` - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/Phase 2
Not yet recruiting	`NCT05576480` - SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer	Phase 2
Completed	`NCT00911170` - PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study	Phase 3
Completed	`NCT00378313` - A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer	Phase 2
Recruiting	`NCT06120387` - Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
Active, not recruiting	`NCT05868317` - Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer	Phase 2
Terminated	`NCT01318642` - Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT01327612` - Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)	Phase 2
Completed	`NCT03644056` - Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT03093922` - A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer	Phase 2
Recruiting	`NCT05766800` - Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT06416007` - Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors	Phase 2
Active, not recruiting	`NCT03024489` - Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05877573` - Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer	N/A
Terminated	`NCT00819169` - QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06020430` - Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy	N/A
Active, not recruiting	`NCT06102057` - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC	Phase 2
Recruiting	`NCT05802394` - The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer	N/A
Recruiting	`NCT05763641` - TAD After Chemotherapy in Locally Advanced Breast Cancer